Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Arendt, C.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(3)
+
-
Availability
Open access
(1)
+
-
Metadata Only
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(3)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(3)
+
-
Author
Arendt, C.
(3)
+
-
Heijde, D. van der
(3)
+
-
Mountian, I.
(3)
+
-
Vollenhoven, R. van
(3)
+
-
Bingham, C.O.
(2)
+
-
Burmester, G.R.
(2)
+
-
Bykerk, V.P.
(2)
+
-
Emery, P.
(2)
+
-
Furst, D.E.
(2)
+
-
Mariette, X.
(2)
+
-
Purcaru, O.
(2)
+
-
Tatla, D.
(2)
+
-
VanLunen, B.
(2)
+
-
Weinblatt, M.E.
(2)
+
-
Show more
Language
en
(3)
+
-
Search results
(1 - 3 of 3)
show grid
show list
save search
Emery, P.; Bingham, C.O.; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; ... ; Weinblatt, M.E.
2017
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Article / Letter to editor
open access
Emery, P.; Bingham, C.O.; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; ... ; Weinblatt, M.E.
2016
Response to: "Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
Article / Letter to editor
metadata only
Smolen, J.S.; Vollenhoven, R. van; Kavanaugh, A.; Strand, V.; Vencovsky, J.; Schiff, M.; ... ; Heijde, D. van der
2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Article / Letter to editor
metadata only